Dose escalation schema. Decitabine (20 mg/m²) was administered either as a short infusion (Arm A) or by continuous infusion (Arm B) for 3, 5, or 7 days (dose levels 1, 2, and 3, respectively) before standard infusional cytarabine, daunorubicin induction chemotherapy (7 + 3). Bone marrow and blood specimens were collected for pharmacodynamic analyses before and immediately after decitabine administration. The red line represents the hypothesized reactivation of chemosensitizing tumor suppressor genes (TSGs) resulting from epigenetic priming.